Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06318689
Other study ID # 2023/0211/OB
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 5, 2024
Est. completion date May 5, 2026

Study information

Verified date February 2024
Source University Hospital, Rouen
Contact Emmanuel EB BESNIER, PHD
Phone 02 32 88 89 90
Email emmanuel.besnier@chu-rouen.fr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The goal of this observational study is to assess in situ vascular function, glycocalyx and microcirculation in postoperative vasoplegic shock following cardiac surgery with cardiopulmonary bypass. The main question is to investigate the relationship between NO-dependent vasomotor reserve and the presence of vasoplegic shock following cardiac surgery with cardiopulmonary bypass. Participants will have two visits, during which a number of non-invasive examinations will be carried out to study glycocalyx, microcirculation and vascular function. Biological and morphological data will be collected up to 3 months after inclusion, as well as information on treatments administered and outcome. Researchers will compare a group of patients with vasoplegic shock against a group without vasoplegic shock in order to study possible alterations in function in the vasoplegic shock group.


Description:

Objective : the primary objective of this study is to explore in situ the glycocalyx, the microcirculation and vascular function in postoperative vasoplegic shock following cardiac surgery with CPB. Secondary objectives are to study links between vascular function and damage to the glycocalyx and microcirculation and patient prognosis, in particular their impact on fluid balance. Method : Constitution of a single-centre prospective cohort study of 124 patients. Patients hospitalised in the cardiac intensive care unit after cardiac surgery with CPB will be consecutively included from 4 to 24 hours after surgery: 62 patients with vasoplegic shock (noradrenaline > 0.05µg/kg/min for at least 4 hours and after correction of any hypovolaemia), 62 patients without vasoplegic shock. Endothelial function will be assessed using the flow-mediated dilation (FMD) method to test brachial artery vasodilation mediated by nitric oxide (NO) after induced ischemia. Microcirculation and glycocalyx will be evaluated using GlycoCheck, providing several measurements of microcirculation and glycocalyx using Sidestream Dark Field technology (mucosal illumination by a green LED and continuous x20 magnification video recording at the sublingual mucosa level). Various endothelial and inflammatory markers will also be measured (VCAM-1, syndecan, endothelin, interleukin-6). Each patient will be assessed at inclusion and 48 hours using GlycoCheck, FMD, and endothelial measurements, then followed through their medical records for 90 days, where a follow-up call will be conducted to assess outcomes. Collected information will include routine care data (morphological data, vital signs, laboratory tests, fluid balance, scores, treatments, surgical data). Both groups will be compared using statistical tests, and risk factors for developing vasoplegic shock will be explored through logistic regression. Univariable analysis followed by multivariable logistic regression with backward data inclusion will then be performed to identify risk factors for vasoplegic syndrome within the entire cohort (necessarily including FMD and GlycoCheck). A p-value <0.05 will be considered statistically significant.


Recruitment information / eligibility

Status Recruiting
Enrollment 124
Est. completion date May 5, 2026
Est. primary completion date February 5, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients aged between 18 and 80 years old - Patient undergoing cardiac surgery with cardiopulmonary bypass - Hospitalised in a cardiac surgical unit, between 4 and 24 hours after the end of cardiopulmonary bypass, after volemic optimisation Exclusion Criteria: - Sepsis at inclusion - Cardiac transplant - Circulatory assistance - Known alteration of the microcirculation - Any condition contraindicating measurement via Glycocheck or flux mediated dilatation measurement - New surgery within 48 hours of the operation - Person deprived of liberty by an administrative or judicial decision or person placed under legal protection / sub-guardianship or guardianship - Patient refusal

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Rouen University Hospital Rouen Normandie

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Association between the percentage of brachial artery variation measured by the flow-mediated vasodilation method and the presence of vasoplegic shock at incusion. Association between the percentage of brachial artery variation measured by the flow-mediated vasodilation method and the presence of vasoplegic shock. At inclusion
Secondary Association between the percentage of brachial artery variation measured by the flow-mediated vasodilation method and the presence of vasoplegic shock at 48 hours. Association between the percentage of brachial artery variation measured by the flow-mediated vasodilation method and the presence of vasoplegic shock. At 48 hours
Secondary Pefused boundary region (PBR, µm) obtained from Glycocheck with the presence of vasoplegic shock. Pefused boundary region is an index given by the Glycocheck, a reflection of the alteration of the glycocalyx.
The higher the value, the more impaired the glycocayx.
At inclusion and at 48 hours
Secondary Microvascular blood flow (10^3 microns^3 / sec / mm^2) obtained from Glycocheck with the presence of vasoplegic shock Microvascular blood flow (10^3 microns^3 / sec / mm^2), given by the Glycocheck, is an estimation of the microcirculation. The lower the value, the more it indicates a deterioration in microcirculation. At inclusion and at 48 hours
Secondary Total density (number of 10 micron long vessel segments with diameter of 4 to 25 microns per tissue surface area /mm^2) obtained from Glycocheck with the presence of vasoplegic shock Total density (number of 10 micron long vessel segments with diameter of 4 to 25 microns per tissue surface area /mm^2), given by the Glycocheck, is an estimation of the density ot the vessels. The lower the value, the more it indicates a deterioration in microcirculation. At inclusion and at 48 hours
Secondary Endothelial function markers (Endothelin-1, pg/mL) with the presence of vasoplegic shock Endothelin-1 (pg/ml), indicates vasoconstriction, will be measured by ELISA. At inclusion and at 48 hours
Secondary Endothelial function markers (syndecan-1, pg/mL) with the presence of vasoplegic shock Endothelin-1 (pg/ml), indicates endothelium ateration, will be measured by ELISA. At inclusion and at 48 hours
Secondary Endothelial function markers (interleukin-6, pg/mL) with the presence of vasoplegic shock Interleukin-6 (pg/ml), indicates inflammation, will be measured by ELISA. At inclusion and at 48 hours
Secondary Endothelial function markers (VCAM-1, pg/mL) with the presence of vasoplegic shock VCAM-1 (pg/ml), indicates endothelium ateration, will be measured by ELISA. At inclusion and at 48 hours
Secondary Multivariate analysis explaining the occurrence of vasoplegic shock. Model constructed from variables found to be associated in univariate analysis. At inclusion and at 48 hours
Secondary Multivariate analysis explaining the occurrence of an altered perfused boundary region (µm). Model constructed from variables found to be associated in univariate analysis. At inclusion and at 48 hours
See also
  Status Clinical Trial Phase
Terminated NCT04293744 - Acute Kidney Injury After Cardiac Surgery N/A
Completed NCT01184521 - Masimo CO-Oximeter Study Phase 0
Completed NCT05537168 - Bayesian Networks in Pediatric Cardiac Surgery
Completed NCT05737147 - Comparison of the Accuracy and Precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature.
Completed NCT04269109 - Opioid Sparing Pain Management Strategy
Completed NCT04911413 - Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery Phase 4
Recruiting NCT02580292 - Diagnostic Accuracy of Doppler Resistive Indices for Early Diagnosis of Acute Kidney Injury .
Completed NCT02457572 - Pulse Pressure Variation Measured During Valsalva Maneuver to Predict Fluid Responsiveness Under Open-chest Condition N/A
Completed NCT00997217 - The Effect of Remote Ischemic Preconditioning in the Cardiac Surgery Phase 1
Recruiting NCT05454735 - Glycemic Variability and Autonomic Nervous System in Cardiac Surgery Patients
Completed NCT01169441 - Lead Extract Study N/A
Completed NCT00336908 - Inflammatory Responses to Lipid Emulsions in Children Before and After Open Heart Surgery Phase 2/Phase 3
Terminated NCT05308589 - CPPF After General Cardiac Surgery N/A
Recruiting NCT03163238 - Dexmedetomidine and the Inflammatory Response in Pediatric Cardiac Surgery Phase 2
Completed NCT02329158 - Disinvestment in Hydroxyl-ethyl Starches (HES) for Cardiac Surgery
Completed NCT01029314 - Pilot Study of the Genius(TM)2 Tympanic Thermometer in Cardiac Patients Requiring Cardiopulmonary Bypass N/A
Completed NCT00459082 - A Pharmacokinetic Study of Dexmedetomine in Infants Phase 1
Completed NCT00122018 - An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery Phase 2
Terminated NCT03709693 - Clinical Outcomes in Patients Treated With SternaLock Blu
Completed NCT03976947 - Impact of Lung Recruitment Maneuvers on Driving Pressure in Cardiac Surgery